Delving into the Latest Updates on Hepatera LLC with Synapse

A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination with Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients with Chronic Hepatitis D - Myrcludex B in chronic hepatitis D

开始日期2016-05-19

申办/合作机构

Hepatera LLC

NCT02888106 / Completed临床2期

A Multicenter, Open-label, Randomised, Comparative, Parallel-Arm, Phase II Study to Assess Efficacy and Safety of Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent

Randomised, Comparative, Parallel-Arm Study to Assess Efficacy and Safety of Myrcludex B in Combination with Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients with Chronic Viral Hepatitis B with Delta-agent

开始日期2016-04-01

申办/合作机构

Hepatera LLC

NCT03546621 / Completed临床2期

A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D

This is a multicenter, open-label, randomized clinical trial to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination with Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients with Chronic Hepatitis D

开始日期2016-02-16

申办/合作机构

Hepatera LLC

[+1]

100 项与 Hepatera LLC 相关的临床结果

登录后查看更多信息

0 项与 Hepatera LLC 相关的专利（医药）

登录后查看更多信息

100 项与 Hepatera LLC 相关的药物交易

登录后查看更多信息

100 项与 Hepatera LLC 相关的转化医学

登录后查看更多信息